While MD An­der­son has been mak­ing trou­ble for Patrick Soon-Sh­iong’s can­cer moon shot cam­paign, the high-pro­file biotech bil­lion­aire has been mak­ing his case di­rect­ly with Pres­i­dent-elect Don­ald Trump, talk­ing about in­no­va­tion and health­care pri­or­i­ties over a meal Sat­ur­day night.

Soon-Sh­iong, who made a for­tune sell­ing Abrax­ane to Cel­gene, was on the week­end agen­da of the busy pres­i­dent-elect, who’s been in­ter­view­ing po­ten­tial Cab­i­net picks and hob­nob­bing with the Re­pub­li­can elite at the Trump Na­tion­al Golf Club in Bed­min­ster, New Jer­sey. The line­up in­clud­ed one-time harsh crit­ic, and cur­rent fan, Mitt Rom­ney. And Soon-Sh­iong’s din­ner with vice-pres­i­dent-elect Pence and Trump was spiced with some biotech chat­ter.

Soon-Sh­iong be­comes the first promi­nent in­dus­try fig­ure to speak di­rect­ly with Trump since his stun­ning up­set vic­to­ry. So what did they talk about?

“Dr. Patrick Soon-Sh­iong joined Pres­i­dent-elect Trump and Vice Pres­i­dent-elect Pence for din­ner this evening,” says the Trump camp’s lat­est mis­sive on his meet­ings Sat­ur­day. “The renowned doc­tor has ap­peared on the cov­er of Forbes for his ad­vances in find­ing a cure for can­cer. They dis­cussed in­no­va­tion in the area of med­i­cine and na­tion­al med­ical pri­or­i­ties that need to be ad­dressed in our coun­try.”

No one has told me any­thing about this talk, but the in­dus­try will be work­ing hard to in­flu­ence Trump’s po­si­tion and poli­cies on pric­ing new drugs—where the in­no­va­tion rub­ber hits the road. Soon-Sh­iong’s sit-down with Trump comes as in­dus­try ex­ecs ap­pear to be gain­ing con­fi­dence that his in­au­gu­ra­tion may well boost in­vestors’ con­fi­dence in the in­dus­try.

Soon-Sh­iong’s camp did not an­swer my query about the de­tails of their con­ver­sa­tion, but the bil­lion­aire didn’t miss a chance to spot­light his ac­cess in a tweet.

In­cred­i­ble hon­or din­ing w/Pres-elect @re­al­Don­aldTrump last night. He tru­ly wants to ad­vance #health­care for all. https://t.co/z6qRV9Cf­Do

— Dr. Pat Soon-Sh­iong (@Dr­Pat­Soon­Sh­iong) No­vem­ber 20, 2016

89bio said its drug was better than placebo at lessening fibrosis without worsening nonalcoholic steatohepatitis, or NASH, in two of three dose groups.

The San Francisco biotech said it thinks the Phase IIb data pave the way for a potential Phase III, following in the footsteps of another biotech in its drug class, Akero Therapeutics. To fund a late-stage study, CEO Rohan Palekar told Endpoints News 89bio “would need to raise additional capital,” with the company having about $188 million at the end of last year.

The National Institutes of Health has again declined to use so-called “march-in” rights to lower the price of Astellas and Pfizer’s prostate cancer drug Xtandi despite being invented at UCLA with grants from the US Army and NIH.

“Given the remaining patent life and the lengthy administrative process involved for a march-in proceeding, NIH does not believe that use of the march-in authority would be an effective means of lowering the price of the drug,” NIH told prostate cancer patients Robert Sachs and Clare Love, in a letter shared with Endpoints News. The institutes’ analyses found Xtandi “to be widely available to the public,” an indication that there was not a pressing need for the US to act.